

TABLE E-1 Baseline Subject Characteristics					
	Complete One-Year Data		Complete Two-Year Data		Unimpaired Comparison Group (N = 16)
	CN Group (N = 15)	DMPN Group (N = 19)	CN Group (N = 8)	DMPN Group (N = 5)	
Age* (yr)	54.5 ± 177; 10.1	57.5 ± 177; 11.1	52.6 ± 177; 4.5	64.8 ± 177; 11.5	27.4 ± 177; 5.1
Male:female ratio (no. of subjects)	8/7	8/11	5/3	4/1	8/8
Height* (m)	1.77 ± 177; 8.3	1.72 ± 177; 8.5	1.79 ± 177; 7.57	1.73 ± 177; 12.54	1.72 ± 177; 10.2
Weight* (kg)	114 ± 177; 29	96 ± 177; 26	114 ± 177; 34	88 ± 177; 26	76 ± 177; 18
Body mass index* (kg/m <sup>2</sup> )	36 ± 177; 7	32 ± 177; 8	35 ± 177; 9	29 ± 177; 7	25 ± 177; 5
Race (White/Black/Asian) (no. of subjects)	11/4/0	13/6/0	6/2/0	3/5/0	12/1/3
Diabetes type (1/2) (no. of subjects)	2/10	1/18	2/4	0/5	
Diabetes duration* (yr)	17.7 ± 177; 9.2	14.0 ± 177; 12.9	19.8 ± 177; 10.9	11.5 ± 177; 11.4	
Hemoglobin A1c* (%)	7.9 ± 177; 1.8	7.9 ± 177; 2.1	8.7 ± 177; 1.7	6.6 ± 177; 0.5	
Biothesiometry* (V)	48 ± 177; 2	28 ± 177; 2			
Joint position sense absent at ankle/toe (no. of subjects)	1/12	0/5			
Idiopathic neuropathy (no. of subjects)	3	0	2	0	
Involved side (right/left) (no. of subjects)	6/9	9/10	6/2	4/1	8/1
CN group event characteristics					
Duration from onset to enrollment* (mo)	4.5 ± 177; 5				
First CN event/recurrent CN event (no. of subjects)	11/4				
Treatment (cast/brace) (no. of subjects)	9/6				
Treatment duration (cast/brace)* (d)	106 ± 177; 40/175 ± 177; 93				
Eichenholtz classification					
Stage I: fragmentation/dislocation	13		8		
Stage II: coalescence	2		0		
*The values are given as the mean and the standard deviation.					